论文部分内容阅读
本文对影响乙肝导向干扰素临床疗效的某些因素进行了初步分析。结果发现，乙肝导向干扰素对慢性活动性肝炎（ＣＡＨ）的疗效好，而对慢性迁延性肝炎（ＣＰＨ）和无症状乙肝病毒携带者（ＡＳＣ）疗效差。治疗前血清ＡＬＴ＞１００ＩＵ／Ｌ及病程４年以内者疗效好。同时还证实，慢性乙肝病人（２３．３３％）体内存在干扰素α中和抗体。乙肝导向干扰素治疗后可促进抗体的产生，并且可影响其疗效。
In this paper, some factors influencing the clinical efficacy of hepatitis B-directed interferon have been preliminarily analyzed. The results showed that hepatitis B-directed interferon has a good curative effect on chronic active hepatitis (CAH) and poor curative effect on chronic persistent hepatitis (CPH) and asymptomatic hepatitis B virus carriers (ASC). Pretreatment serum ALT> 100IU / L and duration of less than 4 years were effective. Also confirmed that chronic hepatitis B patients (23.33%) in vivo presence of interferon alpha neutralizing antibodies. Hepatitis B-guided interferon therapy can promote the production of antibodies, and can affect its efficacy.